148 related articles for article (PubMed ID: 22294603)
1. Adventitious Agents: Issues and Considerations during Pre-Approval Reviews and Inspections.
Eltermann J
PDA J Pharm Sci Technol; 2011; 65(6):694-7. PubMed ID: 22294603
[TBL] [Abstract][Full Text] [Related]
2. FDA post-approval expectations for adventitious virus contamination prevention.
Friedman RL
PDA J Pharm Sci Technol; 2011; 65(6):698-712. PubMed ID: 22294604
[TBL] [Abstract][Full Text] [Related]
3. Current testing methods and challenges for detection of adventitious viruses.
Khan AS
PDA J Pharm Sci Technol; 2011; 65(6):627-33. PubMed ID: 22294589
[TBL] [Abstract][Full Text] [Related]
4. Case study of apparent virus contamination in biopharmaceutical product at centocor.
Hendricks LC; Vacante DA
PDA J Pharm Sci Technol; 2011; 65(6):612-3. PubMed ID: 22294583
[TBL] [Abstract][Full Text] [Related]
5. Identification and remediation of a cell culture virus contamination.
Jones N
PDA J Pharm Sci Technol; 2011; 65(6):615. PubMed ID: 22294585
[TBL] [Abstract][Full Text] [Related]
6. Introduction to workshop: adventitious viruses in biologics--detection and mitigation strategies.
Khan AS; Hughes P; Wiebe M
PDA J Pharm Sci Technol; 2011; 65(6):544-6. PubMed ID: 22294575
[TBL] [Abstract][Full Text] [Related]
7. Current European regulations for control of adventitious virus safety.
Blümel J
PDA J Pharm Sci Technol; 2011; 65(6):568-79. PubMed ID: 22294579
[TBL] [Abstract][Full Text] [Related]
8. Overview of emerging technologies to detect adventitious agents.
Onions D
PDA J Pharm Sci Technol; 2011; 65(6):654-9. PubMed ID: 22294592
[TBL] [Abstract][Full Text] [Related]
9. Viral Safety of Plasma-derived Products.
Farshid M
PDA J Pharm Sci Technol; 2011; 65(6):737-53. PubMed ID: 22294608
[TBL] [Abstract][Full Text] [Related]
10. Application of quality by design in the control of adventitious viruses: gaps in current processes in the prevention of virus contaminants.
Cherney B
PDA J Pharm Sci Technol; 2011; 65(6):754-66. PubMed ID: 22294609
[TBL] [Abstract][Full Text] [Related]
11. A biotech production facility contamination case study--minute mouse virus.
Skrine J
PDA J Pharm Sci Technol; 2011; 65(6):599-611. PubMed ID: 22294582
[TBL] [Abstract][Full Text] [Related]
12. A microarray platform for virus detection and identification.
Munroe D
PDA J Pharm Sci Technol; 2011; 65(6):691. PubMed ID: 22294600
[TBL] [Abstract][Full Text] [Related]
13. Summary of breakout session e.
Brorson K; Lubiniecki A
PDA J Pharm Sci Technol; 2011; 65(6):616-9. PubMed ID: 22294586
[TBL] [Abstract][Full Text] [Related]
14. Contamination by porcine circovirus type 1: findings, investigations, and learnings.
Piérard I
PDA J Pharm Sci Technol; 2011; 65(6):614. PubMed ID: 22294584
[TBL] [Abstract][Full Text] [Related]
15. Summary of Breakout Session B: Regulatory Expectations for CGMP.
Sausville R; Cazeault C
PDA J Pharm Sci Technol; 2011; 65(6):713-4. PubMed ID: 22294605
[TBL] [Abstract][Full Text] [Related]
16. Massively parallel sequencing for the detection of adventitious viruses.
Kolman JL
PDA J Pharm Sci Technol; 2011; 65(6):663-7. PubMed ID: 22294594
[TBL] [Abstract][Full Text] [Related]
17. Breakout Session A: Elimination or Treatment of High-risk Raw Materials.
Kiss R; Drews R
PDA J Pharm Sci Technol; 2011; 65(6):767-77. PubMed ID: 22294610
[TBL] [Abstract][Full Text] [Related]
18. Use of DOP-PCR in Non-Specific Virus Detection.
Uhlenhaut C; McClenahan S; Krause PR
PDA J Pharm Sci Technol; 2011; 65(6):681-4. PubMed ID: 22294597
[TBL] [Abstract][Full Text] [Related]
19. Regulatory approaches for control of viral contamination of vaccines.
McClenahan S; Uhlenhaut C; Krause PR
PDA J Pharm Sci Technol; 2011; 65(6):557-62. PubMed ID: 22294577
[TBL] [Abstract][Full Text] [Related]
20. Summary of breakout session f: facility and equipment decontamination strategies.
Norwood LP; Suvarna K
PDA J Pharm Sci Technol; 2011; 65(6):625-6. PubMed ID: 22294588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
